Since ERα36 has been shown to collaborate with other estrogen or growth factor receptors in numerous cancer cells, our results also raise the possibility that an excess of ERα36 protein could be a dominant positive activator of either the G protein-coupled estrogen receptor GPER, or the EGFR downstream signaling. The gene discussed is EGFR; the disease is cancer.